Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H30ClFN2O3 |
| Molecular Weight | 521.022 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@@H]([C@@H](C1=CNC2=C1C=C(C)C=C2F)C3=CC=C(Cl)C=C3)C4=CC=C(C=C4)C(=O)NCCC(O)=O
InChI
InChIKey=FYRJJCYFYLLOSC-LXFBAYGMSA-N
InChI=1S/C30H30ClFN2O3/c1-3-4-23(19-5-7-21(8-6-19)30(37)33-14-13-27(35)36)28(20-9-11-22(31)12-10-20)25-17-34-29-24(25)15-18(2)16-26(29)32/h5-12,15-17,23,28,34H,3-4,13-14H2,1-2H3,(H,33,37)(H,35,36)/t23-,28+/m1/s1
MK 3577 is an orally active glucagon receptor antagonist which was under development by Merck & Co for the treatment of type 2 diabetes mellitus. MK 3577 demonstrate activity in cellular models and preclinical trials. In phase II clinical trials MK 3577 shows good efficacy and acceptable level of adverse events, but no further development reports were published.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
46240797
Created by
admin on Tue Apr 01 16:48:36 GMT 2025 , Edited by admin on Tue Apr 01 16:48:36 GMT 2025
|
PRIMARY | |||
|
DB14957
Created by
admin on Tue Apr 01 16:48:36 GMT 2025 , Edited by admin on Tue Apr 01 16:48:36 GMT 2025
|
PRIMARY | |||
|
03TW1410NL
Created by
admin on Tue Apr 01 16:48:36 GMT 2025 , Edited by admin on Tue Apr 01 16:48:36 GMT 2025
|
PRIMARY | |||
|
1019112-29-8
Created by
admin on Tue Apr 01 16:48:36 GMT 2025 , Edited by admin on Tue Apr 01 16:48:36 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
